Fulcrum Therapeutics Inc
NASDAQ:FULC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
US |
|
Apollo Tyres Limited
NSE:APOLLOTYRE
|
IN |
|
Anant Raj Ltd
NSE:ANANTRAJ
|
IN |
|
Azerion Group NV
AEX:AZRN
|
NL |
|
Sonae SGPS SA
F:YSON
|
PT |
|
Ranger Energy Services Inc
NYSE:RNGR
|
US |
|
Monolithic Power Systems Inc
NASDAQ:MPWR
|
US |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SZSE:300619
|
CN |
|
Patanjali Foods Ltd
NSE:PATANJALI
|
IN |
|
Copenhagen Capital A/S
CSE:CPHCAP ST
|
DK |
|
Ercros SA
MAD:ECR
|
ES |
|
S
|
S&P Global Inc
XETRA:MHL
|
US |
|
T
|
Times Guaranty Ltd
NSE:TIMESGTY
|
IN |
|
A
|
Avanza Bank Holding AB
F:1JJA
|
SE |
|
ENGlobal Corp
NASDAQ:ENG
|
US |
|
J
|
JMC Electronics Co Ltd
TWSE:6552
|
TW |
|
N
|
NFC Corp
KOSDAQ:265740
|
KR |
|
Human Health Holdings Ltd
HKEX:1419
|
HK |
|
Country Garden Services Holdings Co Ltd
HKEX:6098
|
CN |
|
L
|
Limelight Networks Inc
F:LNK
|
US |
|
W
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
US |
|
C
|
Citrix Systems Inc
LSE:0HYR
|
US |
|
MBB SE
XETRA:MBB
|
DE |
|
S
|
Starflex PCL
SET:SFLEX
|
TH |
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2019-07-18. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm has developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The firm uses its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
Robust HbF Induction: Pociredir 20 mg showed a mean increase in fetal hemoglobin (HbF) from 7.1% to 19.3% at 12 weeks, with 58% of patients achieving at least 20% HbF—levels linked to meaningful clinical benefit.
Encouraging Hematologic Effects: The trial saw a 1.1 g/dL mean rise in total hemoglobin and significant reductions in hemolysis markers (LDH down 34%, indirect bilirubin down 40%) and reticulocytes (down 42%), reflecting improved red blood cell health.
VOC Reduction Trend: Seven of twelve patients reported no vaso-occlusive crises (VOCs) during treatment, with observed VOCs (6 in 5 patients) well below the 16 events expected from baseline rates.
Favorable Safety Profile: Pociredir was generally well tolerated at 20 mg, with no treatment-related serious adverse events or dose-limiting toxicities, and all observed adverse events resolved with continued dosing.
Regulatory and Phase III Plans: Fulcrum plans to initiate a registration-enabling trial in the second half of 2026 and is engaging with US and European regulators, supported by data viewed as strong enough to move forward.
Competitive Positioning: Management believes pociredir has a two-year head start over other oral HbF inducers in development, with a focus on maximizing global access.
